Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Infrared Light Detects and Quantifies Malaria Parasites

By LabMedica International staff writers
Posted on 08 May 2014
A novel way to detect malaria, one of the most common and deadly diseases in the world, that also quantifies the early stage parasites, has been developed. More...


The quick and inexpensive test uses infrared light to detect malaria at a very early stage of its development by looking for fatty acids in the parasite and could dramatically reduce the number of people who die from the disease.

Scientists at Monash University (Clayton, VIC, Australia) maintained cultured Plasmodium falciparum parasites synchronized to ring stages by sorbitol lysis. High parasitemia ring-stage cultures were obtained by seeding uninfected red blood cells with purified schizont-stage parasites that were allowed to reinvade under shaking conditions overnight, reducing multiple infections.

The method to rapidly detect and quantify different stages of malaria parasites, including ring and gametocyte forms, used attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FT-IR) and partial least-squares regression (PLS). A Bruker model Equinox 55 (Bruker Optic; Ettingen, Germany) FT-IR spectrometer fitted with a nitrogen-cooled mercury–cadmium–telluride (MCT) detector and a golden gate diamond ATR accessory (Specac Limited; Orpington, UK) was used for spectral acquisition. ATR-FTIR utilizes infrared light to detect the vibrations of molecules and essentially depicts the entire chemistry of the system under investigation.

The scientists already knew that fatty acids were a marker for the disease from previous studies at the Australian Synchrotron. The Synchrotron allowed the team to see the different life stages of the parasite and the variation in its fatty acids. They then applied these insights to develop an inexpensive laboratory based test that has the potential to be portable. The results confirmed the ability of ATR-FT-IR to detect parasitaemia levels down to 0.00001%.

Bayden R. Wood, PhD, the senior author of the study, said, “Not only did the test give clear results within minutes, it gave a clear indication of malaria at a much earlier stage of infection than current tests on the market. Now that we can detect the early stages of a parasite's life in the blood stream the disease will be much easier to test and treat. The big advantage of our test is that it doesn't need scientists and expensive equipment. This has the potential to dramatically reduce the number of people dying from this disease in remote communities.” The study was published on April 2, 2014, in the journal Analytical Chemistry.

Related Links:

Monash University
Bruker Optic
Specac Limited



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.